Topas Therapeutics is a spin-out of Evotec, a global drug discovery and development partnership company. It has developed a unique technology for the induction of antigen-specific immune tolerance. This new approach has the potential to treat autoimmune diseases, allergies and drug induced immune reactions in a more efficient and safe way.
When ambition meets ambition
The technology platform that Topas Therapeutics has developed is within an emerging field that recently has gained increasing momentum with investors and pharma companies. Topas’ unique approach has the potential to fundamentally change the treatment of autoimmune disorders.
Together, we build a leading company
The funds are used to expand and accelerate the Company’s proprietary tolerance induction platform and to develop its products through proof-of-concept studies.